CAMBRIDGE, Mass. and
HERZLIYA-PITUACH, Israel,
Sept. 8, 2014 /PRNewswire/
-- Immune Pharmaceuticals Inc. (NASDAQ and NASDAQ OMX First
North Premier, Stockholm: "IMNP";
"Immune" or "the Company"), today announced it will be featured as
a presenting company at the 16th Annual Rodman
& Renshaw Global Investment Conference, sponsored by
H.C. Wainwright & Co.,
LLC. The conference is being held September 8-10, 2014,
at the New York Palace Hotel in New York
City.
Dr. Daniel Teper, CEO of Immune,
recently NASDAQ Capital Market listed company, will provide an
overview of the Company's business during the live presentation,
including initiation of phase II clinical trials with its lead
drug, Bertilimumab, and partnering process for its phase III drug,
AmiKet™. Company management will be available to participate in
one-on-one meetings with investors who are registered to attend the
conference.
Event: 16th Annual Rodman & Renshaw
Global Investment Conference
Date: Wednesday, September 10,
2014
Time: 2:30 PM (Eastern Time)
Location: New York Palace Hotel, Holmes II Salon (4th
floor)
The presentation webcast will be accessible within a few days
and for the next 90 days at www.immunepharmaceuticals.com.
About Immune Pharmaceuticals Inc.
Immune Pharmaceuticals Inc. applies a personalized approach to
treatment, developing novel, highly targeted antibody therapeutics
to improve the lives of patients with inflammatory diseases and
cancer. The Company's lead product candidate, Bertilimumab,
is in clinical development for moderate to severe
ulcerative colitis and Crohn's Disease as well as bullous
pemphigoid, an orphan auto-immune dermatological condition, Immune
licensed worldwide rights for systemic indications of Bertilimumab
from iCo Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011, while iCo retained rights to all
ophthalmic indications. iCo originally licensed the exclusive
world-wide rights to Bertilimumab in 2006 from MedImmune, the
Global Research and Development Arm of AstraZeneca. Immune's
pipeline also includes NanomAbs®, antibody nanoparticle conjugates,
for the targeted delivery of chemotherapeutics. and AmiKet™, a
Neuropathic Pain drug candidate ready for Phase III. AmiKet has
received Fast Track designation for chemotherapy induced
neuropathic pain and Orphan Drug Designation for Post Herpetic
Neuralgia.
For more information, visit Immune's website at
www.immunepharmaceuticals.com, the content of which is not a part
of this press release.
Erik Penser Bankaktiebolag is engaged as Immune´s Certified
Adviser on NASDAQ OMX First North Premier.
Forward-Looking Statements
This news release and any oral statements made with respect to
the information contained in this news release contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. You are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal" or the negative of
those words or other comparable words to be uncertain and
forward-looking. Such forward-looking statements include
statements that express plans, anticipation, intent, contingency,
goals, targets, future development and are otherwise not statements
of historical fact. These statements are based on our current
expectations and are subject to risks and uncertainties that could
cause actual results or developments to be materially different
from historical results or from any future results expressed or
implied by such forward-looking statements. Factors that may cause
actual results or developments to differ materially include: the
risks associated with the adequacy of our existing cash resources
[and our ability to continue as a going concern; the risks
associated with our ability to continue to meet our obligations
under our existing debt agreements; the risk that clinical trials
for bertilimumab or AmiKet™ will not be successful; the risk that
Bertilimumab, AmiKet™ or compounds arising from our NanomAb®
program will not receive regulatory approval or achieve significant
commercial success; the risk that we will not be able to find a
partner to help conduct the Phase III trials for AmiKet™ on
attractive terms, a timely basis or at all; the risk that our other
product candidates that appeared promising in early research and
clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later-stage clinical trials; the risk that we will
not obtain approval to market any of our product candidates; the
risks associated with dependence upon key personnel; the risks
associated with reliance on collaborative partners and others for
further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our
history of operating losses since our inception; the highly
competitive nature of our business; risks associated with
litigation; and risks associated with our ability to protect our
intellectual property. These factors and other material risks are
more fully discussed in our periodic reports, including our reports
on Forms 10-K, 10-Q and 8-K and other filings with the U.S.
Securities and Exchange Commission. You are urged to carefully
review and consider the disclosures found in our filings which are
available at www.sec.gov or at www.immunepharmaceuticals.com. You
are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be wrong due to
inaccurate assumptions, unknown risks or uncertainties or other
risk factors. We expressly disclaim any obligation to publicly
update any forward-looking statements contained herein, whether as
a result of new information, future events or otherwise, except as
required by law.
SOURCE Immune Pharmaceuticals Inc.